Encapsulates paclitaxel (PTX), a widely used chemotherapeutic agent, within a nanoparticle designed to maximize drug delivery to tumors and drug accumulation within tumors.

Manufactured through a proprietary 16-step nanoprocess, producing biocompatible and biodegradable nanoparticles.

Designed to minimize nonspecific exposure of paclitaxel in the bloodstream and to normal cells.

Demonstrated outstanding safety and high tolerability across extensive preclinical studies.

Established high No Observed Adverse Effect Levels (NOAELs) across 30+ preclinical studies and approximately 4,000 pages of supporting study data, with no treatment-related adverse effects observed.

No treatment-related adverse events were observed in completed preclinical studies.

Significantly greater tumor reduction than Abraxane and the highest level of cancer cell death in a preclinical pancreatic cancer model.

Water dispersible formulation that forms an aqueous suspension, with a nanoparticle size of less than 100 nm, about one-thousandth the width of a human hair.
※ A nanometer is one billionth of a meter (10⁻⁹ m).